Induction, Propagation, and Activity of Host Nitric Oxide: Lessons from Leishmania Infection

Trends in Parasitology

Volumn 31, Issue 12, 2015, Pages 653-664

  Olekhnovitch, Romain ^a,b,c   Bousso, Philippe ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSTITUT PASTEUR   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Antimicrobial activity; Immunopathology; Leishmania; Nitric oxide; T cell

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; NITRIC OXIDE; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR;

ANTIMICROBIAL ACTIVITY; DISEASE ASSOCIATION; HOST; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LEISHMANIA; LEISHMANIASIS; LEUKOCYTE ADHERENCE; MEDIATOR; MICROENVIRONMENT; NONHUMAN; PARASITE CONTROL; PROTEIN EXPRESSION; REVIEW; SKIN INFECTION; T LYMPHOCYTE; TISSUE INJURY; TISSUE LEVEL; ANIMAL; ENZYME INDUCTION; ENZYMOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ENZYME INDUCTION; HUMANS; LEISHMANIA; LEISHMANIASIS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; SIGNAL TRANSDUCTION;

EID: 84949313119     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2015.08.001     Document Type: Review

References (100)

1. Kaye P., Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat. Rev. Microbiol. 2011, 9:604-615.
2. Mougneau E., et al. Cell biology and immunology of Leishmania. Immunol. Rev. 2011, 240:286-296.
3. Sacks D., Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2002, 2:845-858.
4. Alexander J., Brombacher F. T helper 1/T helper 2 cells and resistance/susceptibility to Leishmania infection: is this paradigm still relevant?. Front. Immunol. 2012, 3:80.
5. Filipe-Santos O., et al. A dynamic map of antigen recognition by CD4 T cells at the site of Leishmania major infection. Cell Host Microbe 2009, 6:23-33.
6. Liew F.Y., et al. Resistance to Leishmania major infection correlates with the induction of nitric oxide synthase in murine macrophages. Eur. J. Immunol. 1991, 21:3009-3014.
7. Wei X.Q., et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995, 375:408-411.
8. Peters N.C., et al. In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 2008, 321:970-974.
9. Goncalves R., et al. Platelet activation attracts a subpopulation of effector monocytes to sites of Leishmania major infection. J. Exp. Med. 2011, 208:1253-1265.
10. Charmoy M., et al. Neutrophil-derived CCL3 is essential for the rapid recruitment of dendritic cells to the site of Leishmania major inoculation in resistant mice. PLoS Pathog. 2010, 6:e1000755.
11. León B., et al. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 2007, 26:519-531.
12. Serbina N.V., Pamer E.G. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat. Immunol. 2006, 7:311-317.
13. Serbina N.V., et al. Sequential MyD88-independent and -dependent activation of innate immune responses to intracellular bacterial infection. Immunity 2003, 19:891-901.
14. Peters W., et al. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:7958-7963.
15. Bosschaerts T., et al. Tip-DC development during parasitic infection is regulated by IL-10 and requires CCL2/CCR2, IFN-gamma and MyD88 signaling. PLoS Pathog. 2010, 6:e1001045.
16. Serbina N.V., et al. Monocyte-mediated defense against microbial pathogens. Annu. Rev. Immunol. 2008, 26:421-452.
17. De Trez C., et al. iNOS-Producing inflammatory dendritic cells constitute the major infected cell type during the chronic Leishmania major infection phase of C57BL/6 resistant mice. PLoS Pathog. 2009, 5:e1000494.
18. Bogdan C. Nitric oxide synthase in innate and adaptive immunity: an update. Trends Immunol. 2015, 36:161-178.
19. Gao J.J., et al. Cutting edge: bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J. Immunol. 1999, 163:4095-4099.
20. Mühl H., et al. Inducible NO synthase and antibacterial host defence in times of Th17/Th22/T22 immunity. Cell. Microbiol. 2011, 13:340-348.
21. Lima-Junior D.S., et al. Inflammasome-derived IL-1β production induces nitric oxide-mediated resistance to Leishmania. Nat. Med. 2013, 19:909-915.
22. Pautz A., et al. Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 2010, 23:75-93.
23. Farlik M., et al. Nonconventional initiation complex assembly by STAT and NF-κB transcription factors regulates nitric oxide synthase expression. Immunity 2010, 33:25-34.
24. Olekhnovitch R., et al. Collective nitric oxide production provides tissue-wide immunity during Leishmania infection. J. Clin. Invest. 2014, 124:1711-1722.
25. MacMicking J.D. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat. Rev. Immunol. 2012, 12:367-382.
26. + T cell response. J. Exp. Med. 1995, 181:961-971.
27. Diefenbach A., et al. Type 1 interferon (IFNα/β) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite. Immunity 1998, 8:77-87.
28. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J. Immunol. 2002, 168:3992-4000.
29. + T cells is sufficient to mediate T helper cell type 1 development. J. Exp. Med. 1998, 188:1651-1656.
30. Egen J.G., et al. Intravital imaging reveals limited antigen presentation and T cell effector function in mycobacterial granulomas. Immunity 2011, 34:807-819.
31. Chtanova T., et al. Dynamics of T cell, antigen presenting cell, and pathogen interactions during recall responses in the lymph node. Immunity 2009, 31:342-355.
32. + T cells rely on a cytokine gradient to control intracellular pathogens beyond sites of antigen presentation. Immunity 2012, 37:147-157.
33. Huse M., et al. T cells use two directionally distinct pathways for cytokine secretion. Nat. Immunol. 2006, 7:247-255.
34. Muraille E., et al. Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response. J. Immunol. 2003, 170:4237-4241.
35. Kostka S.L., et al. Distinct roles for IL-1 receptor type I signaling in early versus established Leishmania major infections. J. Invest. Dermatol. 2006, 126:1582-1589.
36. Kautz-Neu K., et al. IL-1 signalling is dispensable for protective immunity in Leishmania-resistant mice. Exp. Dermatol. 2011, 20:76-78.
37. Von Stebut E., et al. Interleukin 1α promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J. Exp. Med. 2003, 198:191-199.
38. Voronov E., et al. IL-1-induced inflammation promotes development of leishmaniasis in susceptible BALB/c mice. Int. Immunol. 2010, 22:245-257.
39. Naik S., et al. Compartmentalized control of skin immunity by resident commensals. Science 2012, 337:1115-1119.
40. Green S.J., et al. Leishmania major amastigotes initiate the l-arginine-dependent killing mechanism in IFN-γ-stimulated macrophages by induction of tumor necrosis factor-α. J. Immunol. 1990, 145:4290-4297.
41. Nashleanas M., et al. Control of Leishmania major infection in mice lacking TNF receptors. J. Immunol. 1998, 160:5506-5513.
42. Derouich-Guergour D., et al. Tumour necrosis factor α receptors: role in the physiopathology of protozoan parasite infections. Int. J. Parasitol. 2001, 31:763-769.
43. Wilhelm P., et al. Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF. J. Immunol. 2001, 166:4012-4019.
44. Chakour R., et al. Both the Fas ligand and inducible nitric oxide synthase are needed for control of parasite replication within lesions in mice infected with Leishmania major whereas the contribution of tumor necrosis factor is minimal. Infect. Immun. 2003, 71:5287-5295.
45. Xynos I.D., et al. Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe. Emerg. Infect. Dis. 2006, 15:956-959.
46. Albakri Q.A., Stuehr D.J. Intracellular assembly of inducible NO synthase is limited by nitric oxide-mediated changes in heme insertion and availability. J. Biol. Chem. 1996, 271:5414-5421.
47. Hinz B., et al. Nitric oxide inhibits inducible nitric oxide synthase mRNA expression in RAW 264.7 macrophages. Biochem. Biophys. Res. Commun. 2000, 271:353-357.
48. Cho I.J., et al. Repression by oxidative stress of iNOS and cytokine gene induction in macrophages results from AP-1 and NF-κB inhibition mediated by B cell translocation gene-1 activation. Free Radic. Biol. Med. 2005, 39:1523-1536.
49. Robinson M.A., et al. Oxygen-dependent regulation of nitric oxide production by inducible nitric oxide synthase. Free Radic. Biol. Med. 2011, 51:1952-1965.
50. Mahnke A., et al. Hypoxia in Leishmania major skin lesions impairs the NO-dependent leishmanicidal activity of macrophages. J. Invest. Dermatol. 2014, 134:2339-2346.
51. + storage strengthens the antimicrobial barrier function of the skin and boosts macrophage-driven host defense. Cell Metab. 2015, 21:493-501.
52. Hill B.G., et al. What part of NO don't you understand? Some answers to the cardinal questions in nitric oxide biology. J. Biol. Chem. 2010, 285:19699-19704.
53. Brown G.C. Nitric oxide and mitochondrial respiration. Biochim. Biophys. Acta 1999, 1411:351-369.
54. Doulias P-T., et al. Nitric oxide regulates mitochondrial fatty acid metabolism through reversible protein S-nitrosylation. Sci. Signal. 2013, 6:rs1.
55. Lee Y-I., et al. Protein microarray characterization of the S-nitrosoproteome. Mol. Cell. Proteomics 2014, 13:63-72.
56. Wink D.A., et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 1991, 254:1001-1003.
57. Stenger S., et al. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J. Exp. Med. 1996, 183:1501-1514.
58. Bogdan C., et al. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr. Opin. Immunol. 2000, 12:64-76.
59. Bogdan C., et al. Fibroblasts as host cells in latent leishmaniosis. J. Exp. Med. 2000, 191:2121-2130.
60. Fang F.C. Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Invest. 1997, 99:2818-2825.
61. Mauël J., Ransijn A. Leishmania spp.: mechanisms of toxicity of nitrogen oxidation products. Exp. Parasitol. 1997, 87:98-111.
62. Assreuy J., et al. Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur. J. Immunol. 1994, 24:672-676.
63. Mukbel R.M., et al. Macrophage killing of Leishmania amazonensis amastigotes requires both nitric oxide and superoxide. Am. J. Trop. Med. Hyg. 2007, 76:669-675.
64. Lemesre J-L., et al. Leishmania spp.: nitric oxide-mediated metabolic inhibition of promastigote and axenically grown amastigote forms. Exp. Parasitol. 1997, 86:58-68.
65. Pearce E.J., Everts B. Dendritic cell metabolism. Nat. Rev. Immunol. 2015, 15:18-29.
66. Iniesta V., et al. The inhibition of arginase by Nω-hydroxy-l-arginine controls the growth of Leishmania inside macrophages. J. Exp. Med. 2001, 193:777-784.
67. Kropf P., et al. Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. FASEB J. 2005, 19:1000-1002.
68. Das P., et al. Modulation of the arginase pathway in the context of microbial pathogenesis: a metabolic enzyme moonlighting as an immune modulator. PLoS Pathog. 2010, 6:e1000899.
69. Holzmuller P., et al. Phenotypical characteristics, biochemical pathways, molecular targets and putative role of nitric oxide-mediated programmed cell death in Leishmania. Parasitology 2006, 132:S19-S32.
70. Müller A.J., et al. Photoconvertible pathogen labeling reveals nitric oxide control of Leishmania major infection in vivo via dampening of parasite metabolism. Cell Host Microbe 2013, 14:460-467.
71. Fruth U., et al. Leishmania major interferes with antigen presentation by infected macrophages. J. Immunol. 1993, 150:1857-1864.
72. Prina E., et al. Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages. J. Immunol. 1996, 156:4318-4327.
73. Jaramillo M., et al. Leishmania repression of host translation through mTOR cleavage is required for parasite survival and infection. Cell Host Microbe 2011, 9:331-341.
74. Gregory D.J., Olivier M. Subversion of host cell signalling by the protozoan parasite Leishmania. Parasitology 2005, 130(Suppl.):S27-S35.
75. Giudice A., et al. Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis. BMC Infect. Dis. 2007, 7:7.
76. Souza A.S., et al. Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-α production. BMC Infect. Dis. 2010, 10:209.
77. Santos P.L., et al. Leishmania chagasi naturally resistant to nitric oxide isolated from humans and dogs with visceral leishmaniasis in Brazil. Nitric Oxide 2012, 27:67-71.
78. Belkaid Y., et al. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J. Immunol. 2000, 165:969-977.
79. Mishra B.B., et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1β. Nat. Immunol. 2013, 14:52-60.
80. Bogdan C. Regulation of lymphocytes by nitric oxide. Methods Mol. Biol. 2011, 677:375-393.
81. Harari O., Liao J.K. Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr. Pharm. Des. 2004, 10:893-898.
82. Bingisser R.M., et al. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J. Immunol. 1998, 160:5729-5734.
83. Mazzoni A., et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 2002, 168:689-695.
84. Pereira W.F., et al. Myeloid-derived suppressor cells help protective immunity to Leishmania major infection despite suppressed T cell responses. J. Leukoc. Biol. 2011, 90:1191-1197.
85. Lukacs-Kornek V., et al. Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. Nat. Immunol. 2011, 12:1096-1104.
86. Siegert S., et al. Fibroblastic reticular cells from lymph nodes attenuate T cell expansion by producing nitric oxide. PLoS ONE 2011, 6:e27618.
87. Khan O., et al. Regulation of T cell priming by lymphoid stroma. PLoS ONE 2011, 6:e26138.
88. Yang J., et al. T cell-derived inducible nitric oxide synthase switches off TH17 cell differentiation. J. Exp. Med. 2013, 210:1447-1462.
89. Obermajer N., et al. Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. J. Exp. Med. 2013, 210:1433-1445.
90. Vig M., et al. Inducible nitric oxide synthase in T cells regulates T cell death and immune memory. J. Clin. Invest. 2004, 113:1734-1742.
91. Kubes P., et al. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:4651-4655.
92. Kubes P., et al. Endogenous but not exogenous nitric oxide decreases TNF-α-induced leukocyte rolling. Am. J. Physiol. 1997, 273:G628-G635.
93. Fritzsche C., et al. Endothelial nitric oxide synthase limits the inflammatory response in mouse cutaneous leishmaniasis. Immunobiology 2010, 215:826-832.
94. Bogdan C. Nitric oxide and the immune response. Nat. Immunol. 2001, 2:907-916.
95. Kobayashi Y. The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation. J. Leukoc. Biol. 2010, 88:1157-1162.
96. Matthews J.R., et al. Inhibition of NF-κB DNA binding by nitric oxide. Nucleic Acids Res. 1996, 24:2236-2242.
97. Mao K., et al. Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Cell Res. 2013, 23:201-212.
98. Fang F.C., Vazquez-Torres A. Nitric oxide production by human macrophages: there's NO doubt about it. Am. J. Physiol. 2002, 282:L941-L943.
99. Qadoumi M., et al. Expression of inducible nitric oxide synthase in skin lesions of patients with American cutaneous leishmaniasis. Infect. Immun. 2002, 70:4638-4642.
100. Thomas A.C., Mattila J.T. "Of mice and men": arginine metabolism in macrophages. Inflammation 2014, 5:479.